Flurbiprofen
2-(3-Fluoro-4-phenylphenyl)propanoic acid
Drag to rotate. Structure from PubChem CID 3394.
Background
Listing
- Schedules
- Schedule 1 to 4, conditions apply
- Exceptions reach
- Schedule 0
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
1 registered product listed
Counted through the register's ingredient index, which does not reach every record.
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Flurbiprofen | Transact, Aryflam, Strepsils intensive, +2 more | 8.75mg, 50 mg, 100 mg, suppositories, +1 more | 3 applicants | 9 registrations | S1 |
Regulatory status
Where S1 to S4 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 1: sold by a pharmacist, no doctor's prescription needed. At the most restrictive, Schedule 4: prescription-only medicine. The listings below say which applies to which form, strength or pack size.
Schedule S1 to S4, as the Consolidated Schedules list it.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Flurbiprofen
S4: Flurbiprofen
- when intended for ophthalmic use; (S4)
- except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S1)
- except when intended for application to the skin, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0)
- except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
Consolidated Schedules 06 July 2026, lines 6390 to 6407
S3: Flurbiprofen
- except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
- except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i). a maximum of 8,75 milligrams per lozenge; (ii). a maximum treatment period of 3 days; and (iii). a maximum pack size of 15 lozenges. (S1)
- except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0)
- except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
- except when intended for ophthalmic use; (S4)
Consolidated Schedules 06 July 2026, lines 3609 to 3620
S2: Flurbiprofen
- when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
- except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii)a maximum pack size of 15 lozenges. (S1)
- except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks; (S0)
- except when intended for ophthalmic use. (S4)
Consolidated Schedules 06 July 2026, lines 2014 to 2025
S1: Flurbiprofen
- when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S3)
- except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks (S0)
- except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
- except when intended for ophthalmic use. (S4)
Consolidated Schedules 06 July 2026, lines 465 to 482
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.